Related Experiment Videos

Haemodynamic effects of a new anti-anginal drug, diltiazem hydrochloride

Arzneimittel-Forschung
|January 1, 1977
PubMed

Insights

Diltiazem HCl, an anti-anginal drug, reduced cardiac output and work in angina patients. This decrease in myocardial oxygen consumption may benefit angina pectoris.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angina pectoris is a condition characterized by chest pain due to reduced blood flow to the heart.
  • New anti-anginal drugs are continuously being developed to improve patient outcomes.

Purpose of the Study:

  • To investigate the haemodynamic effects of diltiazem HCl in patients with angina pectoris.
  • To assess the impact of diltiazem HCl on cardiac function and oxygen consumption.

Main Methods:

  • The study involved 20 patients diagnosed with angina pectoris.
  • Haemodynamic parameters were measured using the 131I-dilution method.
  • Cardiac catheterization was performed in two specific patients to further evaluate cardiac function.

Main Results:

  • Diltiazem HCl significantly decreased stroke volume, cardiac output, cardiac work, stroke work, and the cardiac output/circulating blood volume ratio.
  • In patients with cardiac catheterization, no changes in Vmax or ejection fraction were observed, but stroke volume decreased.
  • The reduction in cardiac work and stroke work was attributed to diminished venous return and prolonged systemic circulation time.

Conclusions:

  • Diltiazem HCl demonstrates significant haemodynamic effects in patients with angina pectoris.
  • The drug's ability to decrease myocardial oxygen consumption is postulated to provide beneficial effects for angina management.

Related Concept Videos